Symbols / CGEN $2.83 -0.35% Compugen Ltd.

Healthcare • Biotechnology • Israel • NCM
CGEN Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Fundamentals
Scroll to Statements
Market Cap 268.77M Enterprise Value 125.85M Income 35.34M Sales 72.76M Book/sh 1.09 Cash/sh 1.54
Dividend Yield — Payout 0.00% Employees 75 IPO — P/E 7.45 Forward P/E -8.49
PEG 1.29 P/S 3.69 P/B 2.61 P/C — EV/EBITDA 3.96 EV/Sales 1.73
Quick Ratio 6.46 Current Ratio 6.56 Debt/Eq 2.88 LT Debt/Eq — EPS (ttm) 0.38 EPS next Y -0.33
EPS Growth — Revenue Growth 44.77% Earnings 2026-05-18 ROA 14.42% ROE 44.84% ROIC —
Gross Margin 87.29% Oper. Margin 83.23% Profit Margin 48.57% Shs Outstand 94.55M Shs Float 92.41M Short Float 0.99%
Short Ratio 2.88 Short Interest — 52W High 2.94 52W Low 1.23 Beta 2.77 Avg Volume 315.76K
Volume 302.81K Target Price $5.83 Recom None Prev Close $2.84 Price $2.83 Change -0.35%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.83
Mean price target
2. Current target
$2.83
Latest analyst target
3. DCF / Fair value
$4.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.83
Low
$4.00
High
$13.00
Mean
$5.83

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-07 init Lake Street — → Buy $6
2026-01-07 init HC Wainwright & Co. — → Buy $4
2024-05-21 main Truist Securities Buy → Buy $4
2024-03-08 main Truist Securities Buy → Buy $5
2023-12-19 main Stifel Buy → Buy $4
2023-08-23 reit Truist Securities Buy → Buy $4
2023-08-07 reit EF Hutton Buy → Buy $13
2023-06-06 reit EF Hutton — → Buy $13
2023-05-26 reit EF Hutton Buy → Buy $13
2023-05-24 reit EF Hutton Buy → Buy $13
2023-05-16 main Oppenheimer Outperform → Outperform $7
2023-02-28 reit Oppenheimer — → Outperform $8
2023-02-08 down Jefferies Hold → Underperform $1
2023-01-05 init EF Hutton — → Buy $13
2022-11-15 main Oppenheimer — → Outperform $8
2022-08-23 main Truist Securities — → Buy $4
2022-08-08 main JMP Securities — → Market Outperform $4
2022-08-08 main Oppenheimer — → Outperform $12
2022-08-05 down Jefferies Buy → Hold $2
2022-02-25 main Oppenheimer — → Outperform $14
News
RSS: Latest CGEN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-14 LEVINE ZURIT PH.D. Officer — 2,000 $2.80 $5,600
2026-04-14 LEVINE ZURIT PH.D. Officer — 2,000 $1.15 $2,300
2026-04-14 OPHIR ERAN Chief Executive Officer — 5,000 $2.90 $14,521
2026-04-14 OPHIR ERAN Chief Executive Officer — 5,000 $0.83 $4,146
2026-04-10 LEVINE ZURIT PH.D. Officer — 3,125 $2.56 $8,012
2026-04-10 LEVINE ZURIT PH.D. Officer — 3,125 $0.83 $3,233
2026-04-10 LEVINE ZURIT PH.D. Officer — 3,125 $2.56 $8,012
2026-04-10 LEVINE ZURIT PH.D. Officer — 3,125 $0.83 $3,233
2026-04-08 LEVINE ZURIT PH.D. Officer — 7,875 $2.30 $18,758
2026-04-08 LEVINE ZURIT PH.D. Officer — 7,875 $0.83 $6,851
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
72.76
+161.14%
27.86
-16.72%
33.46
+346.12%
7.50
Operating Revenue
72.76
+161.14%
27.86
-16.72%
33.46
+346.12%
7.50
Cost Of Revenue
9.25
+16.66%
7.93
+295.71%
2.00
+105.54%
0.97
Reconciled Cost Of Revenue
9.25
+16.66%
7.93
+295.71%
2.00
+105.54%
0.97
Gross Profit
63.51
+218.62%
19.93
-36.63%
31.45
+382.07%
6.53
Operating Expense
32.19
-7.58%
34.83
-21.65%
44.45
+6.08%
41.90
Research And Development
22.76
-8.27%
24.81
-28.03%
34.47
+12.48%
30.65
Selling General And Administration
9.43
-5.84%
10.02
+0.40%
9.97
-11.34%
11.25
Selling And Marketing Expense
0.54
-6.42%
0.58
+136.07%
0.24
-73.82%
0.93
General And Administrative Expense
8.89
-5.81%
9.44
-3.00%
9.73
-5.70%
10.32
Other Gand A
8.89
-5.81%
9.44
-3.00%
9.73
-5.70%
10.32
Total Expenses
41.44
-3.08%
42.76
-7.96%
46.45
+8.34%
42.87
Operating Income
31.33
+310.37%
-14.89
-14.62%
-12.99
+63.27%
-35.37
Total Operating Income As Reported
31.33
+310.37%
-14.89
-14.62%
-12.99
+63.27%
-35.37
EBITDA
31.80
+320.76%
-14.40
-15.09%
-12.52
+64.13%
-34.89
Normalized EBITDA
32.11
+323.22%
-14.38
-14.95%
-12.51
+64.47%
-35.22
Reconciled Depreciation
0.47
-2.26%
0.49
+2.10%
0.48
-1.24%
0.48
EBIT
31.33
+310.37%
-14.89
-14.62%
-12.99
+63.27%
-35.37
Total Unusual Items
-0.31
-1445.00%
-0.02
-900.00%
-0.00
-100.61%
0.33
Total Unusual Items Excluding Goodwill
-0.31
-1445.00%
-0.02
-900.00%
-0.00
-100.61%
0.33
Special Income Charges
0.00
0.00
+100.00%
-0.01
+41.67%
-0.01
Net Income
35.34
+348.35%
-14.23
+24.12%
-18.75
+44.34%
-33.69
Pretax Income
35.40
+464.58%
-9.71
+0.77%
-9.78
+70.91%
-33.64
Net Non Operating Interest Income Expense
4.38
-15.80%
5.20
+62.06%
3.21
+127.66%
1.41
Interest Expense Non Operating
—
—
—
0.03
Net Interest Income
4.38
-15.80%
5.20
+62.06%
3.21
+127.66%
1.41
Interest Expense
—
—
—
0.03
Interest Income Non Operating
3.90
+11.92%
3.49
+17.87%
2.96
+105.98%
1.44
Interest Income
3.90
+11.92%
3.49
+17.87%
2.96
+105.98%
1.44
Other Income Expense
-0.31
-1445.00%
-0.02
-900.00%
-0.00
-100.61%
0.33
Gain On Sale Of Security
-0.31
-1450.00%
-0.02
-500.00%
0.01
-98.53%
0.34
Tax Provision
0.05
-98.81%
4.52
-49.59%
8.97
+15365.52%
0.06
Tax Rate For Calcs
0.00
-34.78%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.05
-907.61%
-0.00
-900.00%
-0.00
-100.61%
0.08
Net Income Including Noncontrolling Interests
35.34
+348.35%
-14.23
+24.12%
-18.75
+44.34%
-33.69
Net Income From Continuing Operation Net Minority Interest
35.34
+348.35%
-14.23
+24.12%
-18.75
+44.34%
-33.69
Net Income From Continuing And Discontinued Operation
35.34
+348.35%
-14.23
+24.12%
-18.75
+44.34%
-33.69
Net Income Continuous Operations
35.34
+348.35%
-14.23
+24.12%
-18.75
+44.34%
-33.69
Normalized Income
35.61
+350.47%
-14.22
+24.19%
-18.75
+44.76%
-33.95
Net Income Common Stockholders
35.34
+348.35%
-14.23
+24.12%
-18.75
+44.34%
-33.69
Diluted EPS
0.38
+337.50%
-0.16
+23.81%
-0.21
+46.15%
-0.39
Basic EPS
0.38
+337.50%
-0.16
+23.81%
-0.21
+46.15%
-0.39
Basic Average Shares
93.43
+4.35%
89.53
+2.16%
87.63
+1.25%
86.56
Diluted Average Shares
93.82
+4.79%
89.53
+2.16%
87.63
+1.25%
86.56
Diluted NI Availto Com Stockholders
35.34
+348.35%
-14.23
+24.12%
-18.75
+44.34%
-33.69
Gain On Sale Of PPE
0.00
0.00
+100.00%
-0.01
+41.67%
-0.01
Total Other Finance Cost
-0.47
+72.27%
-1.71
-585.20%
-0.25
-1025.93%
0.03
Line Item Trend 2023-12-31
Total Assets
121.33
Current Assets
114.58
Cash Cash Equivalents And Short Term Investments
50.69
Cash And Cash Equivalents
13.89
Other Short Term Investments
36.80
Receivables
61.32
Accounts Receivable
61.00
Other Receivables
0.32
Prepaid Assets
2.21
Restricted Cash
0.36
Total Non Current Assets
6.75
Net PPE
2.54
Gross PPE
7.90
Accumulated Depreciation
-5.36
Properties
0.00
Machinery Furniture Equipment
4.26
Other Properties
1.33
Leases
2.31
Non Current Prepaid Assets
1.23
Other Non Current Assets
—
Total Liabilities Net Minority Interest
55.77
Current Liabilities
26.27
Payables And Accrued Expenses
11.36
Payables
3.50
Accounts Payable
3.50
Current Accrued Expenses
7.86
Employee Benefits
3.40
Pensionand Other Post Retirement Benefit Plans Current
3.12
Current Debt And Capital Lease Obligation
0.63
Current Capital Lease Obligation
0.63
Current Deferred Liabilities
11.15
Current Deferred Revenue
11.15
Total Non Current Liabilities Net Minority Interest
29.51
Long Term Debt And Capital Lease Obligation
0.72
Long Term Capital Lease Obligation
0.72
Defined Pension Benefit
2.98
Non Current Pension And Other Postretirement Benefit Plans
3.40
Non Current Deferred Liabilities
25.39
Non Current Deferred Revenue
25.39
Stockholders Equity
65.56
Common Stock Equity
65.56
Capital Stock
0.25
Common Stock
0.25
Share Issued
89.24
Ordinary Shares Number
89.24
Treasury Shares Number
0.00
Additional Paid In Capital
539.84
Retained Earnings
-474.53
Gains Losses Not Affecting Retained Earnings
0.00
Other Equity Adjustments
0.00
Total Equity Gross Minority Interest
65.56
Total Capitalization
65.56
Working Capital
88.31
Invested Capital
65.56
Total Debt
1.35
Capital Lease Obligations
1.35
Net Tangible Assets
65.56
Tangible Book Value
65.56
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
31.63
-36.23%
49.60
+238.23%
-35.89
-5.20%
-34.11
Cash Flow From Continuing Operating Activities
31.63
-36.23%
49.60
+238.23%
-35.89
-5.20%
-34.11
Net Income From Continuing Operations
35.34
+348.35%
-14.23
+24.12%
-18.75
+44.34%
-33.69
Depreciation Amortization Depletion
0.47
-2.26%
0.49
+2.10%
0.48
-1.24%
0.48
Depreciation
0.47
-2.26%
0.49
+2.10%
0.48
-1.24%
0.48
Depreciation And Amortization
0.47
-2.26%
0.49
+2.10%
0.48
-1.24%
0.48
Other Non Cash Items
-0.48
+69.21%
-1.57
-462.50%
-0.28
—
Pension And Employee Benefit Expense
-0.10
-18.52%
-0.08
-62.00%
-0.05
+38.27%
-0.08
Stock Based Compensation
1.88
-37.78%
3.02
-14.85%
3.55
-17.98%
4.33
Operating Gains Losses
-0.23
-55.70%
-0.15
+13.37%
-0.17
-153.09%
0.32
Net Foreign Currency Exchange Gain Loss
-0.14
-98.53%
-0.07
+47.29%
-0.13
-132.82%
0.39
Gain Loss On Sale Of PPE
-0.00
0.00
-100.00%
0.01
-41.67%
0.01
Change In Working Capital
-5.35
-108.62%
62.05
+399.67%
-20.71
-272.88%
-5.55
Change In Receivables
0.46
-99.24%
59.93
+198.22%
-61.02
-2581.50%
2.46
Changes In Account Receivables
0.00
-100.00%
61.00
+200.00%
-61.00
0.00
Change In Prepaid Assets
0.59
+190.84%
-0.66
-198.35%
0.67
+5450.00%
0.01
Change In Payables And Accrued Expense
1.02
+123.33%
-4.36
-236.39%
3.20
+299.63%
-1.60
Change In Accrued Expense
0.50
+118.59%
-2.69
-283.99%
1.46
—
Change In Payable
0.52
+130.98%
-1.67
-196.25%
1.73
+208.31%
-1.60
Change In Account Payable
0.52
+130.98%
-1.67
-196.25%
1.73
+208.31%
-1.60
Change In Other Working Capital
-7.79
-209.92%
7.08
-80.60%
36.53
+706.89%
-6.02
Change In Other Current Assets
0.48
-12.91%
0.55
-3.17%
0.57
-13.68%
0.66
Change In Other Current Liabilities
-0.11
+78.33%
-0.50
+22.02%
-0.65
+39.27%
-1.06
Investing Cash Flow
30.00
+164.85%
-46.25
-230.25%
35.51
-4.18%
37.06
Cash Flow From Continuing Investing Activities
30.00
+164.85%
-46.25
-230.25%
35.51
-4.18%
37.06
Net PPE Purchase And Sale
-0.30
-160.68%
-0.12
+31.98%
-0.17
+64.54%
-0.48
Purchase Of PPE
-0.31
-159.32%
-0.12
+31.40%
-0.17
+64.68%
-0.49
Sale Of PPE
0.00
+0.00%
0.00
0.00
-100.00%
0.00
Capital Expenditure
-0.31
-159.32%
-0.12
+31.40%
-0.17
+64.68%
-0.49
Net Investment Purchase And Sale
30.32
+166.18%
-45.80
-228.37%
35.68
-4.96%
37.55
Purchase Of Investment
-96.05
+39.87%
-159.75
-197.46%
-53.70
+30.16%
-76.90
Sale Of Investment
126.37
+10.90%
113.95
+27.48%
89.39
-21.90%
114.44
Net Other Investing Changes
-0.02
+95.15%
-0.33
—
—
Financing Cash Flow
10.60
+1814.08%
0.55
-82.02%
3.08
+772.80%
0.35
Cash Flow From Continuing Financing Activities
10.60
+1814.08%
0.55
-82.02%
3.08
+772.80%
0.35
Net Common Stock Issuance
10.54
+1836.58%
0.54
-82.34%
3.08
0.00
Proceeds From Stock Option Exercised
0.07
+630.00%
0.01
0.00
-100.00%
0.35
Net Other Financing Charges
-0.00
—
—
—
Changes In Cash
72.23
+1749.28%
3.91
+44.40%
2.71
-18.03%
3.30
Effect Of Exchange Rate Changes
0.14
+98.53%
0.07
-47.29%
0.13
+132.82%
-0.39
Beginning Cash Position
18.23
+27.88%
14.26
+24.81%
11.42
+34.14%
8.51
End Cash Position
90.60
+396.99%
18.23
+27.88%
14.26
+24.81%
11.42
Free Cash Flow
31.33
-36.69%
49.49
+237.24%
-36.06
-4.21%
-34.60
Interest Paid Supplemental Data
—
—
3.05
+258.22%
0.85
Income Tax Paid Supplemental Data
0.06
-99.59%
13.52
+112541.67%
0.01
—
Common Stock Issuance
10.54
+1836.58%
0.54
-82.34%
3.08
0.00
Issuance Of Capital Stock
10.54
+1836.58%
0.54
-82.34%
3.08
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category